Palliative therapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (durvalumab) for esophageal cancer that has spread to a few other places in the body or is too advanced for surgery. It aims to see if this combination helps with swallowing difficulties and slows the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with esophageal or gastro-esophageal junction cancer (a type of cancer where the stomach meets the esophagus).
- Your cancer has spread to 1–5 spots outside the main tumor area, or it's locally advanced and can't be removed with surgery or cured with standard chemo-radiation.
- You have trouble swallowing (dysphagia) that requires some treatment.
- You are well enough to be up and about for at least half the day (ECOG score 0–2).
- Your doctor expects you to live longer than 12 weeks.
- You weigh more than 30 kg (66 pounds).
- You have not had prior chemotherapy or radiation for esophageal cancer (except for pain relief to bones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (bemosubaymab), a targeted therapy (anlotinib), radiation therapy, and chemotherapy for patients with esophageal cancer that has spread to a limited number of spots (no more than 5). The goal is to see if this combination can shrink or control the cancer.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests combining chemotherapy with an immunotherapy drug called durvalumab before and after surgery for stomach or lower esophagus cancer. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a new combination of chemotherapy drugs and radiation for advanced esophageal cancer that cannot be removed with surgery. The goal is to see if this treatment can help shrink the cancer and improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.